Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ISET 25: Drug Delivery Devices: Paclitaxel Drug-Coated Balloons and Drug-Eluting Stents
Author(s): Marianne Brodmann Added: 1 year ago
ISET 2025 - How have drug delivery devices changed over the years, and what are the novel technologies and therapeutic agents?Dr Marianne Brodmann (Medical University of Graz, AT) joins us onsite at ISET 2025 to discuss the current landscape of drug delivery devices, from paclitaxel drug-coated balloons to drug-eluting stents. Dr Brodmann discusses evolving technologies, including bioresorbable… View more

Intervention

Vascular Disease and Surgery
Added: 6 months ago Source:  Radcliffe Cardiology
AUTHOR: Greg GuilloryThe selection of drug-eluting stents (DES) for percutaneous coronary intervention (PCI) involves balancing efficacy against safety. The SORT OUT XI randomised trial aimed to compare a newer-generation biolimus-eluting stent with a contemporary dual-therapy sirolimus-eluting stent in a real-world patient population, providing crucial head-to-head evidence.¹SORT OUT XI was a… View more

Intervention

MI/ACS
Drug-coated Balloon Angioplasty in Sri Lanka
Author(s): Yanushka Herath , Judy Ranaweera , Thisal Semina , et al Added: 2 months ago

Intervention

Prevention & Chronic Conditions
Stent Underexpansion and Aorto-ostial Lesions Management
Author(s): Luca Paolucci , Asad Shabbir , Marco Lombardi , et al Added: 1 year ago

Imaging & Diagnostics

Intervention
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma , Paula Mota , Billal Patel , et al Added: 1 year ago

Imaging & Diagnostics

Intervention
IVUS123 workflow for PCI
Author(s): Simon J Walsh , Rafael Cavalcante , Kevin Croce , et al Added: 2 weeks ago

Guidelines & Statements

Intervention
LINC 2025: 12-Month Amputation and Readmission Rates from TRUE-PTX
Author(s): Marianne Brodmann Added: 1 year ago
LINC 2025 - 12-month amputation and readmission rates from the TRUE-PTX study suggests endovascular revascularisation for peripheral artery disease (PAD) with drug-eluting devices lead to better outcomes than with bare device therapies.Dr Marianne Brodmann (Medical University of Graz, AT) joins us to discuss the TRUE-PTX study evaluating a database of patients in the US with PAD who have recieved… View more

Intervention

Vascular Disease and Surgery
ACC 25: Optimizing DAPT Duration
Author(s): Hyo-Soo Kim Added: 10 months ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR… View more

Anticoagulation

Intervention
TCT 25: LIFE-BTK: The Esprit™ BTK Drug-Eluting Resorbable Scaffold for Infrapopliteal Lesions
Author(s): Sahil Parikh Added: 3 months ago
TCT 2025 - Three-year findings from LIFE-BTK show the Esprit™ BTK scaffold is a durable and effective treatment option for patients with CLTI.Dr Sahil Parikh (Columbia University Vagelos College of Physicians & Surgeons, New York, US) joins us to share the three-year findings from LIFE-BTK (NCT04227899). The randomized controlled trial aimed to evaluate the safety and efficacy of the Esprit™ BTK… View more

Intervention

Vascular Disease and Surgery
CREST-2: Stenting Benefits Asymptomatic Carotid Stenosis
Added: 1 week ago Source:  Radcliffe Vascular
The optimal management for asymptomatic carotid stenosis has been a subject of debate, particularly with advancements in medical therapy. New findings from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) provide clarity, suggesting a benefit for carotid-artery stenting when added to intensive medical management.¹MethodologyCREST-2 involved… View more

Intervention

Prevention & Chronic Conditions